Breckenridge Pharmaceutical – Recall of propranolol extended-release capsules

- On November 16, 2026, Breckenridge Pharmaceutical announced a voluntary, consumer level recall of one lot of propranolol hydrochloride extended-release 60 mg capsules due to potential metal contamination.

- Propranolol extended-release capsules were distributed nationwide between October 26, 2026 and November 4, 2026.

Product Description	NDC#	Lot# (Expiration Date)
Propranolol hydrochloride extended-release capsules, USP, 60 mg	51991-817-01	PK25110035 (5/2029)

- Propranolol is used to treat or manage the following conditions:
    - High blood pressure (hypertension)
    - Chest pain caused by coronary artery disease (angina)
    - Prevention of migraine headaches
    - Symptoms associated with hypertrophic subaoritic stenosis, a condition involving thickening of the heart muscle that can obstruct blood flow

- Use of product from the affected lot could potentially cause injury to the soft tissues in the oral cavity, esophagus, stomach, or intestine.

- To date, Breckenridge is not aware of any adverse events assessed to be related to this recall.

- Consumers should immediately stop taking product from the lot subject to this recall and contact their physician or healthcare provider for medical advice and replacement instructions.

- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

- Contact Qualanex, Breckenridge's designated recall service provider, Monday through Friday, 9:00 a.m. to 5:00 p.m. ET by phone at **1-855-736-0807** or by email at **recall@qualanex.com** for questions regarding this recall.